Usa state Pennsylvania covid-19 vaccine DNA medicines Usa state Pennsylvania

Inovio commences Phase I trial of DNA vaccine for Covid-19

Reading now: 664
www.pharmaceutical-technology.com

Inovio Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) for the investigational new drug (IND) application of its DNA vaccine candidate INO-4800 against Covid-19.

Following approval, the company has commenced a Phase I clinical trial of the vaccine candidate in healthy participants. Inovio leveraged its DNA medicines platform to create the Covid-19 vaccine candidate.

The company’s DNA medicines directly deliver optimised plasmids into cells intramuscularly or intradermally using its hand-held smart device Cellectra.

The Phase I trial will assess INO-4800 in up to 40 healthy adults at the University of Pennsylvania’s Perelman School of Medicine and at the Center for Pharmaceutical Research in the US.

Read more on pharmaceutical-technology.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA